OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal Pain
NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal painFirst patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN LONDON and NEW YORK, Oct. 06, 2026 (GLOBE
Share
Why It Matters
OKYO Pharma started testing a new eye pain medicine on real patients. Watch to see if the medicine works well and is safe.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.